{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:22:46Z","timestamp":1786760566948,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B\/F\/TAF in patients with nucleoside reverse transcriptase inhibitor (NRTI) resistance\u2010associated mutations (RAMs), mainly identified by proviral DNA testing, but data on the efficacy of B\/F\/TAF in patients with NRTI RAMs identified in viraemic plasma are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a retrospective analysis of patients receiving B\/F\/TAF identified by searching electronic health records with eligibility confirmed by review of individual patient records. Patients included were \u2265\u200918\u2009years, had 2019 International Antiviral Socitey\u2010USA (IAS\u2010USA) major RAMs affecting NRTIs detected in viraemic plasma prior to starting B\/F\/TAF and one or more HIV viral load (VL) after starting B\/F\/TAF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all, 50 patients met the study criteria: mean age of 54\u2009years, mean proximal CD4 count of 609 cells\/\u03bcL, 64% male. A total of 46 were virologically suppressed (&lt;\u2009200 copies\/mL) when B\/F\/TAF was initiated, two were treatment\u2010na\u00efve, one stopped prior antiretroviral therapy (ART) and one had a VL of 961 HIV\u20101 RNA copies\/mL on ART. Twenty\u2010nine had one NRTI RAM (24 were M184V\/I), nine had two NRTI RAMs, three had three NRTI RAMs, four had four NRTI RAMs, two had five NRTI RAMs, one had six NRTI RAMs, one had seven RAMs and one had eight NRTI RAMs. At the last VL on B\/F\/TAF, a mean of 18.6\u00a0months after starting B\/F\/TAF, 49 out of 50 had VL &lt;\u2009100 copies\/mL and one had a VL of 208 copies\/mL at 11\u2009months but only filled 5\u00a0months of B\/F\/TAF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>B\/F\/TAF was effective in maintaining HIV VL suppression in patients with previously documented NRTI RAMs without integrase resistance.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13376","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:59:58Z","timestamp":1660697998000},"page":"361-365","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bictegravir\/emtricitabine\/tenofovir alafenamide in patients with genotypic <scp>NRTI<\/scp> resistance"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-0908","authenticated-orcid":false,"given":"Stephen D.","family":"Shafran","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Pharmaceutical Sciences University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Biktarvy US prescribing information Gilead Sciences Foster City CA.https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/biktarvy\/biktarvy_pi.pdf. Accessed January 24 2022."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00419-5"},{"key":"e_1_2_6_8_1","article-title":"Sustained viral suppression after switch to bictegravir\/emtricitabine\/tenofovir alafenamide among clinical trial participants with preexisting M184V\/I. abstract P123","volume":"23","author":"Andreatta K","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_6_9_1","unstructured":"AndreattaK AcostaR D'AntoniML et al.Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir\/emtricitabine\/tenofovir alafenamide. Abstract PE1\/6. EACS2021 London UK October 2021."},{"key":"e_1_2_6_10_1","first-page":"2249","article-title":"Differential detection of M184V\/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs","volume":"75","author":"Margot N","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_6_11_1","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV\u20101","volume":"27","author":"Wensing AM","year":"2019","journal-title":"Top Antivir Med"},{"key":"e_1_2_6_12_1","unstructured":"MicanR deGeaGrela A BuscaC BernardinoJI MontesML MontejanoR et al.Efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in patients with pre\u2010existing NRTI resistances: real world data. Abstract BPD1\/6. EACS2021 London UK October 2021."},{"key":"e_1_2_6_13_1","unstructured":"ArmeniaD ForbiciF BertoliA BernoG MalagninoV GagliardiniR.Virological response and resistance profile in virologically suppressed HIV\u20101 infected individuals switching to a bictegravir based treatment in clinical practice. Abstract BPD1\/2. EACS2021 London UK October 2021."},{"key":"e_1_2_6_14_1","unstructured":"TsaiM\u2010S SunH\u2010Y ChenC\u2010P et al.Co\u2010formulated bictegravir emtricitabine and tenofovir alafenamide (BIC\/F\/TAF) for maintenance of viral suppression in adults with historical virological failure and K65N\/R mutation. Presented at vIAS July2021 Abstract 732."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30065-6"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12024"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)00061-7"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30036-2"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.01.009"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa019"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101609"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:19:22Z","timestamp":1692663562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/hiv.13376"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13376","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"2022-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}